Adapting Health Technology Assessment agency standards for surrogate outcomes in early stage cancer trials: what needs to happen?

References

• Championing oncology relevant endpoints (CORE) in Canada: surrogate endpoints in clinical trials and reimbursement decisions for early-stage cancers. Whitepaper. 2023. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/canada/white-paper/championing-oncology-relevant-endpoints-in-canada-en.pdf
   Google Scholar
• Bruce CS, Brhlikova P, Heath J, et al. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: a cross-sectional study of products authorised 2011-2018. PLOS Med. 2019 Sep 10;16(9):e1002873.
   PubMed Web of Science ®Google Scholar
• Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996 Oct 01;125(7):605–613. doi: 10.7326/0003-4819-125-7-199610010-00011
   PubMed Web of Science ®Google Scholar
• Gyawali B, Hey SP, Kesselheim AS. Evaluating the evidence behind the surrogate measures included in the FDA’s table of surrogate endpoints as supporting approval of cancer drugs. EClinicalMedicine. 2020 Apr;21:100332. doi: 10.1016/j.eclinm.2020.100332
   PubMedGoogle Scholar
• Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019 Jul 1;179(7):906–913. doi: 10.1001/jamainternmed.2019.0462
   PubMed Web of Science ®Google Scholar
• Hey SP, Gyawali B, D’Andrea E, et al. A systematic review and meta-analysis of bevacizumab in first-line metastatic breast cancer: lessons for research and regulatory enterprises. J Natl Cancer Inst. 2020 Apr 1;112(4):335–342. doi: 10.1093/jnci/djz211
   PubMedGoogle Scholar
• Schnog JB, Samson MJ, Gans ROB, et al. An urgent call to raise the bar in oncology. Br J Cancer. 2021 Nov;125(11):1477–1485. doi: 10.1038/s41416-021-01495-7
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164–172. doi: 10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989 Apr;8(4):431–440. doi: 10.1002/sim.4780080407
   PubMed Web of Science ®Google Scholar
• Buyse M, Burzykowski T, Saad ED. The search for surrogate endpoints for immunotherapy trials. Ann Transl Med. 2018 Jun;6(11):231. doi: 10.21037/atm.2018.05.16
   PubMed Web of Science ®Google Scholar
• Hamada T, Kosumi K, Nakai Y, et al. Surrogate study endpoints in the era of cancer immunotherapy. Ann Transl Med. 2018 Nov;6(Suppl 1):S27. doi: 10.21037/atm.2018.09.31
   PubMedGoogle Scholar
• Buyse M, Saad ED, Burzykowski T, et al. Surrogacy beyond prognosis: the importance of “trial-level” surrogacy. Oncology. 2022 Apr 5;27(4):266–271. doi: 10.1093/oncolo/oyac006
   Google Scholar
• Ciani O, Buyse M, Garside R, et al. Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ. 2013 Jan 29;346(jan29 1):f457. doi: 10.1136/bmj.f457
   PubMedGoogle Scholar
• Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-Mutated non-small cell lung cancer. N Engl J Med. 2020 Oct 29;383(18):1711–1723. doi: 10.1056/NEJMoa2027071
   PubMed Web of Science ®Google Scholar
• CADTH Reimbursement Recommendations. Osimertinib. Ottawa, Ontario. 2020.
   Google Scholar
• Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137–147. doi: 10.1056/NEJMoa2304594
   PubMed Web of Science ®Google Scholar
• Grigore B, Ciani O, Dams F, et al. Surrogate endpoints in health technology assessment: an international review of methodological guidelines. PharmacoEconomics. 2020 Oct;38(10):1055–1070. doi: 10.1007/s40273-020-00935-1
   PubMed Web of Science ®Google Scholar
• Pavlovic M, Teljeur C, Wieseler B, et al. Endpoints used for relative effectiveness assessment clinical endpoints amended JA1 guideline final. Int J Technol Assess Health Care. 2014. Nov;30(5):508–13. doi: 10.1017/S0266462314000592
   Web of Science ®Google Scholar
• Pinto A, Naci H, Neez E, et al. Association between the use of surrogate measures in pivotal trials and health technology assessment decisions: a retrospective analysis of NICE and CADTH reviews of cancer drugs. Value Health. 2020 Mar;23(3):319–327.
   PubMed Web of Science ®Google Scholar
• NICE. Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. 2023.
   Google Scholar
• Stewart DJ, Bossé D, Goss G, et al. A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: the Ottawa PFS predictive model. Crit Rev Oncol Hematol. 2020 Apr;148:102896.
   PubMed Web of Science ®Google Scholar
• Joffe MM, Greene T. Related causal frameworks for surrogate outcomes. Biometrics. 2009 Jun;65(2):530–538. doi: 10.1111/j.1541-0420.2008.01106.x
   PubMed Web of Science ®Google Scholar
• Vandenberghe S, Duchateau L, Slaets L, et al. Surrogate marker analysis in cancer clinical trials through time-to-event mediation techniques. Stat Methods Med Res. 2018 Nov;27(11):3367–3385. doi: 10.1177/0962280217702179
   PubMed Web of Science ®Google Scholar
• Zuo H, Yu L, Campbell SM, et al. The implementation of target trial emulation for causal inference: a scoping review. J Clin Epidemiol. 2023 Aug 9;162:29–37.
   PubMed Web of Science ®Google Scholar
• NICE. NICE real-world evidence framework. [cited 2023 Jul]. Available from: https://www.nice.org.uk/corporate/ecd9/resources/nice-realworld-evidence-framework-pdf-1124020816837
   Google Scholar
• Wang SV, Schneeweiss S, Franklin JM, et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA. 2023 Apr 25;329(16):1376–1385. doi: 10.1001/jama.2023.4221
   PubMed Web of Science ®Google Scholar
• Ciani O, Grigore B, Blommestein H, et al. Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across International Health Technology Assessment Agencies. Med Decis Making. 2021 May;41(4):439–452. doi: 10.1177/0272989X21994553
   PubMed Web of Science ®Google Scholar
• Kim C, Prasad V. Strength of validation for surrogate end points used in the US Food and Drug Administration’s approval of oncology drugs. Mayo Clin Proc. 2016 May 10;91(6):713–725.
   Web of Science ®Google Scholar
• Buyse M. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer J. 2009;15(5):421–425. doi: 10.1097/PPO.0b013e3181b9c602
   PubMed Web of Science ®Google Scholar
• Ciani O, Davis S, Tappenden P, et al. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care. 2014 Jul;30(3):312–324. doi: 10.1017/S0266462314000300
   PubMed Web of Science ®Google Scholar
• Gesundheitswesen(IQWiG). IfrQuWi. Aussagekraft von surrogatendpunkten in der onkologie.[Validity of surrogate parameters in oncology. 2011. (Rapid report).IQWiG-Berichte 80.
   Google Scholar
• Institute for Quality and Efficiency in Health Care (IQWiG). Allgemeine Methoden Version 5.0. Version. 2017.
   Google Scholar
• Prasad V, Kim C, Burotto M, et al. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015 Aug;175(8):1389–1398. doi: 10.1001/jamainternmed.2015.2829
   PubMed Web of Science ®Google Scholar
• Ciani O, Buyse M, Garside R, et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol. 2015 Jul;68(7):833–842.
   PubMed Web of Science ®Google Scholar
• Walia A, Haslam A, Prasad V. FDA validation of surrogate endpoints in oncology: 2005-2022. J Cancer Policy. 2022 Dec;34:100364. doi: 10.1016/j.jcpo.2022.100364
   PubMedGoogle Scholar
• Pang H, Yang G, Ho JC, et al. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies. Chin Clin Oncol. 2022 Feb;11(1):7. doi: 10.21037/cco-21-110
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16;377(20):1919–1929. doi: 10.1056/NEJMoa1709937
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342–2350. doi: 10.1056/NEJMoa1809697
   PubMed Web of Science ®Google Scholar
• Hashim M, Pfeiffer BM, Bartsch R, et al. Do surrogate endpoints better correlate with overall survival in studies that did not allow for crossover or reported balanced postprogression treatments? An application in advanced non-small cell lung cancer. Value Health. 2018 Jan;21(1):9–17. doi: 10.1016/j.jval.2017.07.011
   PubMed Web of Science ®Google Scholar
• Meadows KA, Reaney M. Bringing the patient’s perspectives forward in drug development and health-care evaluation. Expert Rev Pharmacoecon Outcomes Res. 2023 Mar;23(3):267–271. doi: 10.1080/14737167.2023.2166492
   PubMed Web of Science ®Google Scholar
• Kim Y, Gilbert MR, Armstrong TS, et al. Clinical outcome assessment trends in clinical trials-contrasting oncology and non-oncology trials. Cancer Med. 2023 Aug;12(16):16945–16957. doi: 10.1002/cam4.6325
   PubMed Web of Science ®Google Scholar
• Hudgens S, Forsythe A, Kontoudis I, et al. Evaluation of quality of life at progression in patients with soft tissue sarcoma. Sarcoma. 2017;2017:2372135. doi: 10.1155/2017/2372135
   PubMedGoogle Scholar
• Khozin S, Miksad RA, Adami J, et al. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer. 2019 Nov 15;125(22):4019–4032. doi: 10.1002/cncr.32383
   PubMed Web of Science ®Google Scholar
• Tanaka S, Matsuyama Y, Ohashi Y. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial. Stat Med. 2017 Aug 30;36(19):2963–2977.
   PubMed Web of Science ®Google Scholar
• Li Y, Taylor JM, Elliot MR, et al. Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials. Biostatistics. 2011;12(3):15. doi: 10.1093/biostatistics/kxq082
   Web of Science ®Google Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011 Apr;64(4):383–394.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 Dec 08;4(23):5988–5999. doi: 10.1182/bloodadvances.2020002827
   PubMed Web of Science ®Google Scholar
• Freidlin B, Korde LA, Korn EL. Timing and reporting of secondary overall survival end points for phase III trials in advanced/metastatic disease. J Clin Oncol. 2023 Oct 10;41(29):4616–4620.
   PubMed Web of Science ®Google Scholar